Immunogenic Peptides and Methods of Use for Treating and Preventing Cancer
Description of Invention:
Rhabdomyosarcoma is a malignant (cancerous), soft tissue tumor found in children. The most common sites are the structures of the head and neck, the urogenital tract, and the arms or legs. The inventors have discovered an epitope that is created by a chromosomal translocation that occurs in about 80% of alveolar rhabdomyosarcoma and can elicit a human cytotoxic T lymphocytes (CTL) response in individuals who express HLA-B7.
Many tumors express mutated tumor associated antigens that often contain T-lymphocyte epitopes. However, the immune system often remains incapable of overtaking the growth potential of the malignant cells. Previous attempts to obtain protective and therapeutic anti-tumor immunity have been moderately successful (Dagher et al., Med Pediatr Oncol 38: 158-164 (2002) and Rodeberg et al., Cancer Immuno Immunother 54: 526-534 (2005)). This present invention seeks to improve on previous attempts by providing more immunogenic peptides that bind to a Major Histocompatibility Complex (MHC) Class I molecule with higher affinity, and fusion proteins comprising at least one of the inventive immunogenic peptides. This discovery involves human T-cell responses to human tumors.
Inventors:
Jay A. Berzofsky et al. (NCI)
Patent Status:
DHHS Reference No. E-312-2005/0 --
U.S. Provisional Application No. 60/773,319 filed 03 Nov 2005
Licensing Status: Available for non-exclusive or exclusive licensing.
In addition, the National Cancer Institute welcomes statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize NCI's technology related to methods of protective and therapeutic immunogenic peptides. Please contact Dr. Patrick Twomey at 301-496-0477 or twomeyp@mail.nih.gov for more information.
Portfolios: Cancer
Cancer -Therapeutics-Immunomodulators and Immunostimulants Cancer -Therapeutics
For Additional Information Please Contact: John Stansberry Ph.D.
NIH Office of Technology Transfer
6011 Executive Boulevard, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-5236
Email: stansbej@mail.nih.gov
Fax: (301) 402-0220
